(Bloomberg) — The U.K. has agreed to buy a million doses of AstraZeneca Plc’s Covid-19 antibody treatment if it succeeds in Phase 3 trials. The company is recruiting 5,000 participants globally to evaluate the effectiveness of the combination, called AZD7442, to prevent infection for up to 12 months in people who can’t be given vaccines or don’t respond well to them. Long-acting antibodies can potentially “treat and prevent disease progression…
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push